



#### **Editor** Josef S Smolen

#### **Associate Editors**

Francis Berenhaum Dimitrios Boumnas Gerd Burmester Mary Crow lain McInnes Thomas Pap David Pisetsky Désirée van der Heijde Kazuhiko Yamamoto

#### **Editorial office**

Annals of the Rheumatic Diseases BMJ Publishing Group Ltd RMA House Tavistock Square London WCIH 9JR, UK +44 (0)20 3655 5889 E: ard@bmj.com
Twitter: @ARD\_BMJ ISSN: 0003-4967 (print) ISSN: 1468-2060 (online) **Impact Factor:** 12.350

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism owners grant editorial freedom tothe Editor of ARD.
ARD follows guidelines on editorial independence
produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2018 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd. Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No. 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

#### **Editorial**

**Contents** 

1391 Ultrasound assessment as predictor of disease b relapse in children and adults with arthritis in clinical stable remission: new findings but still unmet needs

E Gremese, A L Fedele, S Alivernini, G Ferraccioli

# **Viewpoint**

**1394** Overdiagnosis and overtreatment in rheumatology: a little caution is in order R B M Landewé

# Clinical and epidemiological research

1397 Epidemiology and socioeconomic impact of the rheumatic diseases on indigenous people: an invisible syndemic public health problem I Peláez-Ballestas, Y Granados, R Quintana, A Lovola-Sánchez, F Julián-Santiago, C Rosillo, A Gastelum-Strozzi, J Alvarez-Nemegyei, N Santana, A Silvestre, C Pacheco-Tena, M Goñi, C García-García, L Cedeño, B A Pons-Éstel, on behalf of the Latin American Study Group of Rheumatic Diseases in Indigenous Peoples (GLADERPO)

**1405** Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

> L Kearslev-Fleet, R Davies, D De Cock, K D Watson, M Lunt, M H Buch, I D Isaacs, K L Hyrich, the BSRBR-RA Contributors Group

**1413** Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry

S A Bergstra, J C Branco, D Vega-Morales, K Salomon-Escoto, N Govind, C F Allaart, R B M Landewé

1421 Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes

N P Sundlisæter, A-B Aga, I C Olsen, HB Hammer, T Uhlig, D van der Heijde, TK Kvien, SLillegraven, EA Haavardsholm, the ARCTIC study group

**1426** Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA)

> O De Lucia, V Ravagnani, F Pregnolato, A Hila, I Pontikaki, M Gattinara, M Romano, V Gerloni, S Pieropan, A Murgo, M Rossini, R Cimaz, P L Meroni



1432 Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status

> MY Md Yusof, A Psarras, YM El-Sherbiny, EMA Hensor, K Dutton, S Ul-Hassan, A S Zavat, M Shalbaf, A Alase, M Wittmann, P Emery, F. M Vital



**1440** Trimethoprim—sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis

> A Kronbichler, I Kerschbaum, S Gopaluni, I Tieu, F Alberici, R B Jones, R M Smith, DRW Iavne

**1448** Characterisation of the nasal microbiota in granulomatosis with polyangiitis

R L Rhee, A G Sreih, C E Najem, P C Grayson, C Zhao, K Bittinger, R G Collman, P A Merkel

#### Basic and translational research

**1454** Systematic approach demonstrates enrichment 6 of multiple interactions between non-HLA risk variants and HLA-DRB1 risk alleles in rheumatoid arthritis

L-M Diaz-Gallo, D Ramsköld, K Shchetynsky, L Folkersen, K Chemin, B Brynedal, S Uebe, Y Okada, L Alfredsson, L Klareskog, L Padyukov

**1463** Methotrexate and BAFF interaction prevents immunization against TNF inhibitors

S Bitoun, G Nocturne, B Ly, R Krzysiek, P Roques, A Pruvost, A Paoletti, J Pascaud, P Dönnes, K Florence, A Gleizes, A Hincelin-Mery, M Allez, S Hacein-Bey-Abina, F Mackay, M Pallardy, R Le Grand, X Mariette

#### MORE CONTENTS ▶



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals open access scheme.

See http://authors.bmj.com/open-access/



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

http://publicationethics.org/





**1471** Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies

K A van Schie, S Kruithof, P Ooijevaar-de Heer, N I L Derksen, F S van de Bovenkamp, A Saris, G Vidarsson, A E H Bentlage, W Jiskoot, S Romeijn, R I Koning, E Bos, E M Stork, C A M Koeleman, M Wuhrer, G Wolbink, T Rispens

**1480** Apolipoprotein B binds to enolase-1 and aggravates inflammation in rheumatoid arthritis J Y Lee, M J Kang, J Y Choi, J S Park, J K Park, E Y Lee, E B Lee, T Pap, E C Yi, Y W Song

**1490** Non-classical monocytes as mediators of tissue destruction in arthritis

OPHNACCCCSS

A Puchner, V Saferding, M Bonelli, Y Mikami,
M Hofmann, J S Brunner, M Caldera,
E Goncalves-Alves, N B Binder, A Fischer,
E Simader, C-W Steiner, H Leiss, S Hayer,
B Niederreiter, T Karonitsch, M I Koenders,
B K Podesser, J J O'Shea, J Menche, J S Smolen,
K Redlich, S Blüml

- **1498** TLR4+CXCR4+ plasma cells drive nephritis development in systemic lupus erythematosus K Ma, J Li, X Wang, X Lin, W Du, X Yang, F Mou, Y Fang, Y Zhao, X Hong, K W Chan, X Zhang, D Liu, L Sun, L Lu
- **1507** Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus Y Kato, JH Park, H Takamatsu, H Konaka, W Aoki, S Aburaya, M Ueda, M Nishide, S Koyama, Y Hayama, Y Kinehara, T Hirano, Y Shima,
- 1516 Cereblon modulator iberdomide induces degradation of the transcription factors lkaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus

M Narazaki, A Kumanogoh

PH Schafer, YYe, LWu, JKosek, GRingheim, ZYang, LLiu, MThomas, MPalmisano, RChopra

**1524** Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2

H Zhang, C Lin, C Zeng, Z Wang, H Wang, J Lu, X Liu, Y Shao, C Zhao, J Pan, S Xu, Y Zhang, D Xie, D Cai, X Bai

#### Letters

1536 Transmission of rheumatoid arthritis through blood transfusion: a retrospective cohort study S A Just, K Rostgaard, K Titlestad, G Edgren, C Erikstrup, H Ullum, O B Pedersen, K R Nielsen, J Askling, H Lindegaard, H Hjalgrim

**1537** Ultrasonography in psoriatic arthritis: which sites should we scan?

A Zabotti, M Piga, M Canzoni, G Sakellariou, A Iagnocco, C A Scirè, on behalf of the UPSTREAM study group

**1539** Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states

P M Machado, R Landewé, D van der Heijde, Assessment of SpondyloArthritis international Society (ASAS)

1540 Impaired long-term immune protection following pneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE)

K Sacre,T Goulenok, M Bahuaud, C Francois, M Claude Van der Haegen, J-F Alexandra, P Aucouturier, M Hurtado-Nedelec, H Moins-Teisserenc, F Batteux, T Papo

**1542** Reduced salivary secretion contributes more to changes in the oral microbiome of patients with primary Sjögren's syndrome than underlying disease

T A van der Meulen, H J M Harmsen, H Bootsma, S C Liefers, A V Vila, A Zhernakova, R K Weersma, F K L Spijkervet, F G M Kroese, A Vissink

**1544** Coffee consumption and gout: a Mendelian randomisation study S C Larsson, M Carlström

# Miscellaneous

**1546** Correction: Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Stud

### **Electronic pages**

- cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis S Mathieu, B Pereira, A Tournadre, M Soubrier
- e66 Response to: 'Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis' by Mathieu et al C Hua, C Rempenault, B Combe
- reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'

  A A den Broeder, B J F van den Bemt

- 68 Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al M J l'Ami, C L M Krieckaert, M T Nurmohamed, R F van Vollenhoven, T Rispens, M Boers, G J Wolbink
- e69 Acquiring new N-glycosylation sites in variable regions of immunoglobulin genes by somatic hypermutation is a common feature of autoimmune diseases

  A Visser, N Hamza, F G M Kroese, N A Bos
- e70 Response to: 'Acquiring new N-glycosylation sites in variable regions of immunoglobulin genes by somatic hypermutation is a common feature of autoimmune diseases' by Visser et al R D Vergroesen, L M Slot, L Hafkenscheid, M T Koning, H U Scherer, R E M Toes

e71 Increased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself?

V Bruzzese, A Zullo

e72 Response to: 'Increased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself?' by Bruzzese and Zullo

E V Arkema, M Rossides, M Von Euler, E Svenungsson, C Sjöwall, I F Simard

- e73 Use of urate-lowering therapies is not associated with an increased risk of incident dementia in older adults

  YH Lee, G G Song
- e74 Response to: 'Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults' by Lee and Song

J A Singh, J Cleveland